
By a vote of 5-4, the US Supreme Court on Thursday agreed to allow the National Institutes of Health, the largest public funding source for biomedical research in the world, to terminate $783 million in grants linked to DEI initiatives.
In a brief unsigned order, the court granted a request from the Trump administration to pause a ruling by a federal judge in Massachusetts that required the federal government to continue making the payments. Also by a vote of 5-4, the court left in place a different portion of the judge’s ruling, which had thrown out internal NIH guidance documents describing the agency’s policy priorities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze